Filing summary: Vallon Pharmaceuticals, Inc. — Form 10-Q, quarter ended March 31, 2022
Important identity mismatch: Request metadata names GRI Bio, Inc., but the supplied filing is for Vallon Pharmaceuticals, Inc. (ticker VLON). This summary reflects the supplied filing, not GRI Bio.
Business context and reporting period
Vallon is a clinical-stage biopharmaceutical company developing abuse-deterrent medicines for central nervous system disorders. Its lead candidate, ADAIR, is an abuse-deterrent dextroamphetamine formulation; ADMIR is an abuse-deterrent methylphenidate formulation. The financial statements cover the three months ended March 31, 2022, with comparisons to the same 2021 quarter.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $1.271 million | $1.772 million; down $0.5 million |
| General and administrative expense | $1.363 million | $0.830 million; up $0.5 million |
| Total operating expenses | $2.634 million | $2.602 million |
| Net loss | $2.635 million | $2.638 million |
| Basic and diluted loss per share | $0.39 | $0.46 |
| Cash used in operating activities | $2.290 million | $2.948 million |
At March 31, 2022, cash and cash equivalents were $2.543 million and available-for-sale marketable securities were $2.634 million, totaling approximately $5.177 million. Total assets were $5.944 million, total liabilities $2.584 million, and stockholders’ equity $3.360 million. Current assets were $5.757 million versus current liabilities of $2.538 million. The filing reports no product sales and no significant revenue; margins are not meaningful for this pre-revenue company.
Investing activities provided $1.154 million, primarily from sales of marketable securities. Financing activities used $23,000, reflecting finance-lease payments. Cash and cash equivalents decreased by $1.159 million during the quarter. The filing reports no material debt financing outstanding; a prior $350,000 convertible-note financing converted into shares in 2021. The balance sheet includes other liabilities and a finance lease obligation.
Material changes and unusual items
- In March 2022, Vallon announced that the ADAIR SEAL study failed to meet its primary endpoint, Emax Drug Liking. The study enrolled 55 participants; 52 were included in the final analysis. Management said the reference dextroamphetamine performed below expectations, contributing to the lack of statistical significance.
- R&D expense fell primarily because ADAIR registration-development costs declined. G&A expense rose due mainly to directors’ and officers’ insurance, personnel and stock compensation, public-company costs, and consulting fees.
- Q1 2021 included $61,000 of income from forgiveness of a Paycheck Protection Program loan and an $89,000 derivative-liability revaluation expense; neither item recurred in Q1 2022.
- Accumulated deficit was $24.537 million at March 31, 2022. The company reported substantial doubt about its ability to continue as a going concern.
Outlook, risks, and contingencies
Management is assessing the future of ADAIR and ADMIR, has no other candidates in clinical trials, and engaged Ladenburg Thalmann to evaluate strategic alternatives, including a merger, business combination, investment, or asset sale, license, or acquisition. Vallon said it was streamlining operations to preserve cash and expected continued expenses and operating losses. It did not provide a specific cash-runway estimate or financial guidance.
The company warned that additional financing may be required and may not be available on acceptable terms. Without funding, it may delay, reduce, or terminate development, or sell or license candidate rights. If no strategic transaction is completed, the board may consider dissolution and liquidation; any stockholder distribution would depend on timing and reserves for obligations and contingencies. COVID-19-related operational uncertainty also remained. Management reported disclosure controls and procedures were effective and no material change in internal control over financial reporting during the quarter. No legal proceedings were reported.
Investor verification points
- Confirm the issuer: the provided filing is Vallon Pharmaceuticals, Inc., not GRI Bio, Inc.
- Review the SEAL study result and any subsequent decision on ADAIR’s development; the primary endpoint was not met.
- Verify the status and terms of any strategic transaction, financing, or potential liquidation process after the filing date.
- Track cash, marketable securities, operating cash use, and obligations, given the going-concern warning; the filing does not provide a clear cash-runway estimate.
- Assess whether ADMIR will advance, as management had not set out a specific development plan or timeline.